ClinicalTrials.gg
CompletedNCT02095171Updated Feb 10, 2015

Single Ascending Dose Study of PRX002 in Healthy Subjects

A Phase 1 interventional study of PRX002 and Placebo in Parkinson's Disease, sponsored by Prothena Biosciences Limited. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-10.

Sponsored by Prothena Biosciences Limited · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.

02

Conditions studied

  • Parkinson's Disease

Browse trials for

03

In context

Parkinson Disease

4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 3,353 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Prothena Biosciences Limited is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects
  • (BMI) between 18-32 kg/m2 with a minimum weight of 46 kg
  • Female subjects must be surgically sterile or or if of must use
  • Male subjects and their partners of childbearing potential must use contraception

Exclusion criteria

Exclusion Criteria:

  • Positive test for drug of abuse
  • Past or current history of alcohol abuse
  • Positive for , or infection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    PRX002

    Drug: PRX002

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as determined by number of subjects with adverse events

    Time frame: up to 3 months

  2. Determination of pharmacokinetics parameters

    - maximum concentration (Cmax)

    Time frame: up to 3 months

  3. Determination of pharmacokinetics parameters

    - time of the maximum measured concentration (Tmax)

    Time frame: up to 3 months

  4. Determination of pharmacokinetics parameters

    - area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)

    Time frame: up to 3 months

  5. Determination of pharmacokinetics parameters

    - area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)

    Time frame: up to 3 months

  6. Determination of pharmacokinetics parameters

    - elimination rate constant

    Time frame: up to 3 months

  7. Determination of pharmacokinetics parameters

    - terminal elimination half life (t½)

    Time frame: up to 3 months

  8. Determination of pharmacokinetics parameters

    - clearance (CL)

    Time frame: up to 3 months

  9. Determination of pharmacokinetics parameters

    - apparent volume of distribution (Vd)

    Time frame: up to 3 months

Secondary outcomes

  1. Immunogenicity as determined by measurement of anti-PRX002 antibodies

    Time frame: up to 3 months

07

Study locations

1 site
  • San Antonio, Texas, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02095171
Lead sponsor
Prothena Biosciences Limited
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 24, 2014
Start date
Mar 2014
Primary completion
Dec 2014
Last update
Feb 10, 2015

Study contacts

Theresa Neumann, PhD
study director · Clinical Trials Prothena Biosciences Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prasinezumab

Start the discussion